Article Figures & Data
Tables
- Table 1
Risk of breast cancer among female users of H2 blockers in GHC relative to the general population of western Washington State, 1977–1996
Observed Expected SIR 95% CI All users 507 518.2 1.0 0.9–1.1 Time since cohort entry (mo) 0–11 68 76.8 0.9 0.7–1.1 12–59 223 234.8 1.0 0.8–1.1 60–119 154 149.8 1.0 0.9–1.2 120+ 62 56.8 1.1 0.8–1.4 By type(s) of H2 blocker used Cimetidine only 267 281.8 0.9 0.8–1.1 Time since cohort entry (mo) 0–11 30 42.0 0.7 0.5–1.0 12–59 118 122.5 1.0 0.8–1.2 60–119 83 84.3 1.0 0.8–1.2 120+ 36 33.0 1.1 0.8–1.5 Cimetidine and other 165 166.3 1.0 0.8–1.2 Time since cohort entry (mo) 0–11 20 18.2 1.1 0.7–1.7 12–59 62 70.2 0.9 0.7–1.1 60–119 58 54.8 1.1 0.8–1.4 120+ 25 23.2 1.1 0.7–1.6 Other only 75 70.0 1.1 0.8–1.3 Time since cohort entry (mo) 0–11 18 16.6 1.1 0.6–1.7 12–59 43 42.2 1.0 0.7–1.4 60–119 13 10.7 1.2 0.6–2.1 120+ 1 0.6 1.7 0.0–9.4 - Table 2
Risk of prostate cancer among male users of H2 blockers in GHC relative to the general population of western Washington State, 1977–1996
Observed Expected SIR 95% CI All users 403 535.3 0.8 0.7–0.8 Time since cohort entry (mo) 0–11 47 73.0 0.6 0.5–0.9 12–59 176 230.1 0.8 0.7–0.9 60–119 130 167.3 0.8 0.6–0.9 120+ 50 64.9 0.8 0.6–1.0 By type(s) of H2 blocker used Cimetidine only 191 271.7 0.7 0.6–0.8 Time since cohort entry (mo) 0–11 18 33.8 0.5 0.3–0.8 12–59 92 109.4 0.8 0.7–1.0 60–119 54 91.0 0.6 0.4–0.8 120+ 27 37.5 0.7 0.5–1.0 Cimetidine and other 151 180.2 0.8 0.7–1.0 Time since cohort entry (mo) 0–11 13 17.6 0.7 0.4–1.3 12–59 50 71.8 0.7 0.5–0.9 60–119 65 64.0 1.0 0.8–1.3 120+ 23 26.7 0.9 0.5–1.3 Other only 61 83.4 0.7 0.6–0.9 Time since cohort entry (mo) 0–11 16 21.6 0.7 0.4–1.2 12–59 34 48.9 0.7 0.5–1.0 60–119 11 12.3 0.9 0.4–1.6 120+ 0 0.7 0 0.0–5.6a -
a One-sided 97.5% CI.
-
- Table 3
Relation of cimetidine use to risk of breast cancer among female users of H2 blockers in GHC, 1984–1996
Controls (N = 4740) Cases (N = 474) RR (95% CI) N % N % Ever used cimetidine No 793 16.7 82 17.3 1.0 Yes 3947 83.3 392 82.7 1.0 (0.7–1.2) No. of prescriptions Never used 793 16.7 82 17.3 1.0 1 763 16.1 75 15.8 0.9 (0.7–1.3) 2–3 874 18.4 92 19.4 1.0 (0.7–1.4) 4–10 1146 24.2 110 23.2 0.9 (0.7–1.3) 11–20 590 12.4 53 11.2 0.9 (0.6–1.2) 21+ 574 12.1 62 13.1 1.0 (0.7–1.5) Time since first eligible prescription Never used 793 16.7 82 17.3 1.0 <2 yr 953 20.1 88 18.6 0.9 (0.6–1.2) 2 to <5 yr 1134 23.9 109 23.0 0.9 (0.7–1.2 5 to <8 yr 906 19.1 91 19.2 1.0 (0.7–1.3) 8+ yr 954 20.1 104 21.9 1.1 (0.8–1.4) Time since last prescription Never used 793 16.7 82 17.3 1.0 ≤1 yr 1804 38.1 182 38.4 1.0 (0.7–1.3) >1 yr to <2 yr 494 10.4 47 9.9 0.9 (0.6–1.3) 2 to <5 yr 941 19.8 82 17.3 0.8 (0.6–1.2) 5+ yr 708 14.9 81 17.1 1.1 (0.8–1.5) - Table 4
Relation of cimetidine use to risk of prostate cancer among male users of H2 blockers in GHC, 1984–1996
Controls (N = 3920) Cases (N = 392) RR (95% CI) N % N % Ever used cimetidine No 708 18.1 68 17.4 1.0 Yes 3212 81.9 324 82.6 1.0 (0.8–1.4) No. of prescriptions Never used 708 18.1 68 17.4 1.0 1 558 14.2 55 14.0 1.0 (0.7–1.5) 2–3 673 17.2 54 13.8 0.8 (0.6–1.2) 4–10 899 22.9 96 24.5 1.1 (0.8–1.5) 11–20 542 13.8 48 12.2 0.9 (0.6–1.4) 21+ 540 13.8 71 18.1 1.4 (1.0–1.9) Time since first eligible prescription Never used 708 18.1 68 17.4 1.0 <2 yr 681 17.4 54 13.8 0.8 (0.5–1.2) 2 to <5 yr 948 24.2 103 26.3 1.1 (0.8–1.6) 5 to <8 yr 790 20.2 81 20.7 1.1 (0.8–1.5) 8+ yr 793 20.2 86 21.9 1.1 (0.8–1.6) Time since last prescription Never used 708 18.1 68 17.4 1.0 ≤1 yr 1461 37.3 154 39.3 1.1 (0.8–1.5) >1 yr to <2 yr 407 10.4 36 9.2 0.9 (0.6–1.4) 2 to <5 yr 747 19.1 69 17.6 1.0 (0.7–1.4) 5+ yr 597 15.2 65 16.6 1.1 (0.8–1.6)